Gary Gibbons, a cardiologist and scientist at Morehouse School of Medicine in Atlanta, today was named director of the National Heart, Lung, and Blood Institute (NHLBI).
Offered the top job at the NHLBI last year, Gary Gibbons '78 was attracted by the chance to steer an agency with a $3 billion budget for research on heart, lung, and blood disorders. But that wasn’t all. Gibbons, a cardiologist and scientist, also saw the position as an opportunity to address what he calls an "egregious" problem: a dearth of African-American scientists in biomedical research.
On 13 August, cardiologist Gary Gibbons became director of the $3 billion National Heart, Lung, and Blood Institute (NHLBI). Gibbons, who turns 56 next week, comes to the third largest National Institutes of Health (NIH) component from Morehouse School of Medicine in Atlanta, where he founded a research center that studied cardiovascular disease in minorities. He previously was a faculty member at Stanford University and Harvard Medical School.
In this video, 1994 Pew Biomedical Scholar Gary H. Gibbons, M.D., director of the NIH's National Heart, Lung, and Blood Institute, and 2012 Pew Biomedical Scholar Kathryn E. Wellen, Ph.D., a specialist in cancer metabolism and epigenetics from the University of Pennsylvania, discuss the impact that being a Pew Biomedical Scholar has had on their lives and careers.
NHLBI Director Dr. Gary Gibbons is interviewed about a genetic mutation that appears linked to low cholesterol levels. Drug companies are now trying to capitaliza on this genetic finding to produce a new cholesterol drug.
Gary Gibbons will be the next Director of the National Heart, Lung, and Blood Institute (NHLBI). The selection of Gibbons was announced today by the National Institutes of Health Director Francis Collins. Gibbons is the founder and current director of the Cardiovascular Research Institute, chairperson of the Department of Physiology, and professor of physiology and medicine at the Morehouse School of Medicine in Atlanta.
The discovery of a rare genetic mutation and of two women with dazzingly low LDL cholesterol levels who carry the mutation has set off one of the greatest medical chases ever. NHLBI Director Dr. Gary H. Gibbons said thousands of people could be candidates for any treatments that result from this work.
Read about research that is illuminating the molecular mechanisms that can cascade into debilitating heart disease.
In this Wall Street Journal article Gary H. Gibbons, M.D., director of the NIH's National Heart, Lung, and Blood Institute (NHLBI), and NHLBI grantee Paul Ridker, M.D., director of the center for cardiovascular-disease prevention at Brigham and Women's Hospital in Boston, discuss the launch of the NHLBI-supported cardiovascular inflammation reduction trial (CIRT) that will test if treating inflammation can cut the risk of a heart attack or stroke in high-risk individuals.
The NHLBI has a long history of supporting highly productive and pivotal research that has translated into new therapies and improved management for chronic lung diseases. To date, our greatest successes have derived from research focused on the treatment of existing diseases in symptomatic patients, and there has been less research attention on primary prevention of lung diseases. We are intrigued by the promise of new insights into chronic lung disease coming from continuing advances in genetics, the blossoming field of reparative biology, and the applications of new imaging and “omic” technologies in well-characterized patients and populations. These scientific advances embolden us to envision a future in which we challenge the prevailing concept of “chronic lung disease” and contemplate the development of preventive strategies that will preempt the progression to lung disease and/or promote its “remission” toward normal lung physiology and respiratory health.